Objective: To probe into the clinical efficacy of glucocorticoid combined with lauromacrogol in the treatment of strawberry capillary hemangioma in hyperplastic phase and its effects on Bcl-2 and Bax mRNA. Methods: Totally 120 children with strawberry capillary hemangioma in hyperplastic phase admitted into our hospital from May 2015 to Oct. 2017 were extracted to be divided into the observation group and the control group via the random number table

with 60 cases in each group. The control group was treated with conventional glucocorticoid

while the observation group received lauromacrogol combined with glucocorticoid. The efficacy and adverse drug reactions

expression of Bcl-2 and Bax mRNA

serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) before and after treatment of two groups were compared. Results: The total effective rate in the observation group 88.33% was higher than that in the control group 73.33%

the difference was statistically significant (P<0.05). After treatment

serum VEGF and bFGF decreased in both groups

and the observation group was significantly lower than the control group (P<0.05). The expression of Bcl-2 mRNA decreased

and the expression of Bax mRNA increased. The expression of Bcl-2 mRNA in the observation group was lower than that in the control group

and the expression of Bax mRNA was higher than that in the control group (P<0.05). Adverse drug reactions were mainly local swelling

local ulcers

pigmentation

central obesity

and hypertension

and there was no statistically significant difference (P>0.05). Conclusion: The clinical efficacy of glucocorticoid combined with lauromacrogol in the treatment of strawberry capillary hemangioma in hyperplastic phase is significant

which can effectively reduce the expression of Bcl-2 mRNA and promote the expression of Bax mRNA

so as to accelerate the apoptosis of hemangioma cells and improve the efficacy.